Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 2

Peripheral T cell lymphoma: clinical utility of romidepsin

Authors Zain J, Sawey

Received 1 March 2012

Accepted for publication 30 March 2012

Published 13 June 2012 Volume 2012:2 Pages 109—115

DOI https://doi.org/10.2147/BLCTT.S22585

Review by Single-blind

Peer reviewer comments 2


Jasmine Zain, Kathryn Sawey

NYU Langone Medical Center, New York, USA

Introduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant tumor cells after exposure to conventional chemotherapy have led researchers to study indirect targets, like the tumor vasculature. A more recent indirect approach involves targeting the epigenetic modifiers, DNA methyltransferase and histone deacetylase. Histone deacetylase inhibitors have been shown to be active cytotoxic agents in T cell lymphoma. The current treatments approved by the US Food and Drug Administration for relapsed cutaneous T cell lymphoma are vorinostat and romidepsin. The diversity and rarity of peripheral T cell lymphomas present a challenge for effective treatment. With their poor overall survival rate, new targeted therapies need to be developed.

Keywords: peripheral T cell lymphoma, treatment, romidepsin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]